Biohaven closes $200M public offering at $7.50 per share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $26 at Morgan Stanley
November 17, 2025 7:38 AM ESTMorgan Stanley analyst Terence Flynn lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $26.00 (from $54.00) while maintaining a Overweight rating.
The analyst comments "BHVN announced on 10/4 that it received a Complete Response Letter (CRL) from the FDA regarding its NDA for... More
